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Abstract
Background: Studies on imaging of differentiated thyroid cancer (DTC) using 124I often require a multicenter
approach, as the prevalence of DTC is low. Calibration of participating scanners is required to obtain comparable
quantification. As determination of a well-defined range of recovery coefficients is complicated for various reasons,
a simpler approach based on the assumption that the iodine uptake is highly focal with a background that
significantly lacks radioactivity might be more efficient. For each scanner, a linear conversion between known and
observed activity can be derived, allowing quantification that can be traced to a common source for all scanners
within one study-protocol. The aim of this paper is to outline a procedure using this approach in order to set up a
multicenter calibration of PET/CT scanners for 124I.
Methods: A cylindrical polyethylene phantom contained six 2-ml vials with reference activities of ~2, 10, 20, 100,
400, and 2000 kBq, produced by dilution from a known activity. The phantom was scanned twice on PET/CT
scanners of participating centers within 1 week. For each scanner, the best proportional and linear fit between
measured and known activities were derived and based on statistical analyses of the results of all scanners; it was
determined which fit should be applied. In addition, a Bland-Altman analysis was done on calibrated activities with
respect to reference activities to asses the relative precision of the scanners.
Results: Nine Philips (vendor A) and nine Siemens (vendor B) PET/CT scanners were calibrated in a time period of
3 days before and after the reference time. No significant differences were detected between the two subsequent
scans on any scanner. Six fitted intercepts of vendor A were significantly different from zero, so the linear model
was used. Intercepts ranged from −8 to 26 kBq and slopes ranged from 0.80 to 0.98. Bland-Altman analysis of
calibrated and reference activities showed that the relative error of calibrated activities was smaller than that of
uncalibrated activities.
Conclusions: A simplified multicenter calibration procedure for PET/CT scans that show highly focal uptake and
negligible background is feasible and results in more precise quantification. Our procedure can be used in
multicenter 124I PET scans focusing on (recurrent) DTC.
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Background
Iodine-124 (124I) is currently of great interest as a PET/
CT tracer in patients with (metastasized) differentiated
thyroid cancer (DTC) for pre-therapeutic assessment of
iodine avidity of lesions and for dosimetric purposes [1–
4]. Dosimetry requires reliable quantification, and as
gathering strong clinical evidence in this relatively rare
disease requires multicenter studies to ensure sufficient
patient enrollment, calibration of scanners is required
[5]. The concurrent emergence of the European Associ-
ation of Nuclear Medicine (EANM) Research Ltd
(EARL) accreditation procedure for 2-[18F]fluoro-2-de-
oxy-D-glucose (18F-FDG) imaging aims to achieve com-
parable scanner performances across multiple sites
through harmonization of the acquisition of PET/CT
scans [6]. However, in the case of 124I used in DTC pa-
tients, a standardization strategy as used for 18F-FDG is
not adequate because recovery of the partial volume ef-
fect is difficult to determine [7]. Due to the combination
of the low positron abundance (around 25 %) and the
presence of 602-keV non-annihilation photons, image-
derived activity concentrations are inaccurate [7, 8].
Documented recovery coefficients depend on object vol-
ume and shape, background activity, voxel size, and
number of effective iterations [7]. Due to the high speci-
ficity of iodine for thyroid tissue, the uptake in the back-
ground is negligible. This allows to determine the total
activity within the lesions by drawing an oversized vol-
ume of interest (VOI) around the imaged target, avoid-
ing the unknown influence of the partial volume effect.
The lesion uptake in units of activity concentration or
standardized uptake value (SUV, %) can be calculated
from the total activity and the lesion volume, determined
from anatomical imaging, e.g., a CT scan.
By measuring a range of 124I activities in a phantom
experiment, a linear relation between the reference and
measured activities can be derived per scanner. Hence,
measured activities can be converted to calibrated activ-
ities for all scanners used in a multicenter study. Know-
ledge of the inaccuracies of individual scanners allows
for benchmarking and thereby determining underper-
forming scanners. Excluding these scanners will improve
the overall accuracy of the quantification of 124I in a
multicenter study and thereby its quality. The aim of this
paper is to outline a procedure for multicenter calibra-
tion of the total activity of 124I in focal, low-background
areas.
Methods
A cylindrical polyethylene phantom containing six 2-ml
cylindrical glass vials (Fig. 1), representing typical lesion
volumes, was developed in-house. By weighing and di-
luting from a known activity of 124I (BV Cyclotron,
Amsterdam, The Netherlands), reference activities (Ar)
of approximately 2, 10, 20, 100, 400, and 2000 kBq at
reference time (Tr) were obtained and put into the vials.
The activity-series was based on the Thyropet protocol,
the optimized dosimetry protocol by Jentzen et al., and
calculations with the iodine kinetic model described in
ICRP publication 53 [3, 9–11]. No activity in the
Fig. 1 Design of the phantom. All sizes are in millimeters. The height is lower than the smallest axial field of view of the PET/CT scanners
included for calibration. The phantom consists of solid polyethylene (light gray) and contains six openings (indicated 1 to 6; 3 to 6 colored white).
In each opening, a polyethylene socket can be placed tightly, enclosing an amber glass vial (dark gray, wall thickness about 1.5 mm) of 2 mL
inner volume, filled with 124I activity (shaded). The position of the vials in the phantom is such that the 124I positrons (maximum range r) do not
interfere between the vials and do not reach the outside of the phantom. The vials have a neck and screw cap, so the shape and height are
an indication
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background was used. A non-radioactive solution of ap-
proximately 1 mg/mL iodine was used for dilution to
prevent 124I from sticking to the walls. Reference activ-
ities at the time of calibration of the scanners (Tc) were
obtained by correction for decay of 124I (half-life
100.2 h).
The phantom was scanned on 18 PET/CT scan-
ners, nine from Philips (Philips Healthcare, Best, The
Netherlands) (vendor A) and nine from Siemens
(Siemens Medical Solutions, Erlangen, Germany)
(vendor B), during a period of 3 days before and
3 days after the reference time (Table 1). Before the
calibration, a dedicated 124I scan protocol was imple-
mented and tested on each scanner. In the clinical
setting, the duration of a whole-body patient scan
preferably is limited to 30 min. Therefore, the scan
time per axial field of view (FOV) was 2 min for
PET/CT scanners of vendor A and 4 min for scan-
ners of vendor B. This difference is a consequence
of the difference in length of the effective FOV of
the two vendors: ~9 cm for vendor A and ~14–
18 cm for vendor B. The standard energy window
(approximately 350–680 keV) was applied. All com-
mon acquisition corrections were applied, i.e.,
normalization and corrections for scatter and attenu-
ation, decay, and dead time. If the scanner was
EARL-accredited, EARL reconstruction parameters
were used [12]. Else, 2D or 3D ordered subset
expectation maximization (OSEM) reconstructions
with sufficient convergence and a 5-mm full width at
half maximum Gaussian reconstruction filter were
utilized. If available, the time of flight option on the
scanners was applied for acquisitions and in
reconstruction.
Two axial FOVs were centered around the vials and
scanned subsequently. The start time of the scan was de-
fined as the calibration time (Tc). On each scanner, the
phantom was scanned twice; after the first scan, it was
turned 180° around the axial axis to determine the re-
producibility of the quantification procedure.
A large VOI of 110 mL (46 mm diameter, 66 mm
height) was placed around each 2-mL vial (Fig. 2a, d).
No interobserver variation was expected and images
were analyzed by one person (JK) using the open source
software Osirix™ (version 4.1.2, 64 bit) [13]. Measured
activities (Am,0 and Am,180) were obtained for each acqui-
sition (0 and 180°) and vial.
Per scanner, the data points Am,0 and Am,180 were
compared with a two-sided paired t test. If no significant
difference (p < 0.05) was obtained, the measurements
were considered reproducible, and only Am,0 was used
for further analyses. Data points from Am,0 were fitted
by linear regression to the function Am,0 = αcal + βcal ·Ar,
with and without the additional constraint that the inter-
cept α equals zero, so both a proportional and a linear
models were investigated. The standard error of the
Table 1 Characteristics of included scanners
Site no. Vendor ToF Slices (CT) EARLa Reconstruction protocolb Voxel size (mm3)
1 A Yes 16 Yes BLOB-OS-TF 64
2 A No 16 No LOR-RAMLA 64
3 A Yes 16 No BLOB-OS-TF 64
4 A Yes 16 Yes BLOB-OS-TF 64
5 A Yes 16 Yes BLOB-OS-TF 64
6 A Yes 64 No BLOB-OS-TF 64
7 A Yes 64 Yes BLOB-OS-TF 64
8 A Yes 64 Yes BLOB-OS-TF 64
9 A Yes 16 No BLOB-OS-TF 64
10 B No 16 Yes OSEM 2D 14.2
11 B Yes 40 No PSF + TOF 49.8
12 B Yes 64 Yes PSF + TOF 20.2
13 B Yes 40 Yes PSF + TOF 30.4
14 B Yes 64 Yes PSF + TOF 11.6
15 B No 16 No OSEM 3D 82.9
16 B No 16 No OSEM 3D 82.9
17 B No 40 Yes OSEM 3D 21.4
18 B No 40 No OSEM 3D 49.7
aScanner accredited by EANM Research Ltd (EARL)
bReconstruction protocol name as named by vendor in DICOM header
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intercept, Δα, was calculated with a two-sided Student’s
t distribution (p < 0.05). If and only if none of the inter-
cepts differed statistically significant from zero, the
model without intercept, i.e., Am,0 = βcal ·Ar, was applied;
otherwise the model with intercept was used (Am,0 = αcal
+ βcal ·Ar).
The estimated slope and, if applicable, intercept of
each scanner were used to calculate the calibrated
activity, Acal, for each measured activity in each vial, so
Acal =Am,0,cal/βcal or Acal = (Am,0 − αcal)/βcal.
A Bland-Altman analysis was performed for the cali-
brated activities to assess the relative precision of the
scanners. The relative errors between calibrated activity
(Acal) and reference activity (Ar) were calculated for each
scanner as an absolute value: Ecal =│(Ar −Acal)/Ar│.
Subsequently, the measured activities were analyzed with
Bland-Altman, again expressed as an absolute value:
Em,0 =│(Ar −Am,0)/Ar│, to investigate whether calibra-
tion improved the measured activities.
All analyses were carried out in Microsoft Excel for
Windows, version 2003 (Microsoft Corp., Redmond,
WA, USA).
Results
The phantom was scanned on 18 PET/CT scanners, nine
scanners of vendor A and nine of vendor B, in 16 hospi-
tals in The Netherlands (Table 1). Figure 2 shows typical
images obtained from scanners of vendor A and B
(Fig. 2a, d).
No significant difference between the measured activ-
ities Am,0 and Am,180 were found in any of the vials of
any of the scanners tested.
The intercepts (αcal) were significantly different
from zero in six out of nine scanners of vendor A
(range αcal 3–26 kBq, range Δαcal 4–29 kBq). None of
the intercepts derived from scanners of vendor B dif-
fered significantly from zero (range αcal −8–11 kBq,
range Δαcal 1–18 kBq). The significant differences be-
tween intercept and zero found in six scanners im-
plied the use of the linear model for calibration for
all scanners. Applying this model, the βcal for scan-
ners of vendor A ranged from 0.80 to 0.98, whereas
the βcal for scanners of vendor B ranged from 0.85 to
0.97. Two example plots, one scanner of each vendor,
of the measured activity (Am,0) against the reference
Fig. 2 Examples of PET and CT images of axial slices acquired from a scanner of vendor A (a, b; obtained from scanner number 5) and vendor B
(c, d; obtained from scanner number 15) to emphasize the differences between the two scanner vendors. Both scanners were calibrated shortly
after each other, so decay of the reference activities was negligible. At the time of calibration, the top vials contained a reference activity Ar of
2.49 MBq. Clockwise, the other vials contained 2.6, 127, 514, 13, and 26 kBq, respectively. a, c CTAC images, with circular regions of interest
matching with the VOIs (in red). b, d corresponding CT images
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activity Ar, including fit to the linear model, are dis-
played in Fig. 3.
Figure 4 shows the relative errors of the measured ac-
tivities before calibration (blue data points) and the cal-
culated activities after calibration (green data points).
The calibration procedure reduced the relative error in
all decades of reference activities. This is depicted by the
green and blue line in Fig. 4, indicating the average rela-
tive error of the measured and calibrated activities, re-
spectively, for each decade of reference activities. The
data in Fig. 4 also indicate in a higher precision the ma-
jority of scanners of vendor B. If the relative errors of
the measured activities by the scanners are compared to
a reasonably chosen threshold of 50 %, Fig. 4 shows that
the first scanner of vendor A exceeds 50 % at 43 kBq,
while the first scanner of vendor B exceeds this percent-
age at 16 kBq. After calibration, these activities are
12 kBq (vendor A) and 2.6 kBq (vendor B).
Discussion
In this study, we present a calibration procedure attain-
ing calibrated scanners for multicenter studies using 124I
and focusing on DTC and proved it to be feasible. Eight-
een PET/CT scanners across the Netherlands were cali-
brated within 1 week with a convenient and easy to
handle phantom, using a single set of 124I reference
activities and predefined scanner-specific acquisition and
reconstruction protocols. The estimated parameters of
the applied model were reproducible, making the pro-
cedure robust. The calibration resulted in a decrease in
relative errors of calibrated activities compared to (non-
calibrated) measured activities (Fig. 4), making quantita-
tive data comparable among different centers.
Our relatively simple approach could be used in other
clinical multicenter studies focusing on other diseases
and tracers, provided that the assumptions of focal up-
take and negligible background are fulfilled. This might
be the case for other 124I tracers and for 68Ga, 18F, and
81Zr tracers.
Standardized and reliable quantification of 124I PET
imaging is essential in the design of multicenter and
dosimetry studies. For example, in a mono-center
study by Ho et al., dosimetric analysis of multiple 124I
PET/CT scans before and after selumetinib treatment
of patients with radioiodine refractory metastases was
performed. The outcome of this analysis determined
whether a new high dose 131I treatment would be
beneficial [1]. The results of this study are promising;
however, in order to expand and validate these, multi-
center studies are warranted. This underlines the need
for multicenter standardization of scanning and
quantification.
Fig. 3 Graphs reported to centers of the involved scanners as example of the differences between the scanner vendors. Linear fit of measured
and reference activity data according to Am,0 = αcal + βcal · Ar. Top row: scanner number 5 (vendor A; αcal = 13 kBq and βcal = 0.947), bottom row:
scanner number 15 (vendor B; αcal = 5.5 kBq and βcal = 0.901). Note that the graphs on the right side (3a and d) are the same as the corresponding
ones on the left side (3a and c), apart from the scales of the axes. Furthermore, the larger offset αcal of scanner 5 compared to that of scanner 15 can
be foreseen from the larger background signal, shown in a and c, respectively
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The phantom and the procedure were designed with
the aim of being reliable, efficient, and safe. Therefore,
the design of the phantom used no 124I background ac-
tivity. Although different from previously published cali-
bration procedures for other isotopes [6, 14], the
absence of background activity seemed justified from a
clinical perspective, and it simplified the calibration pro-
cedure significantly. Iodine uptake is highly specific for
thyroid tissue and very limited to only a few non-thyroid
tissues, like the salivary glands, gastric mucosa, and
choroid plexus [15]. These are, however, not in areas of
clinical relevance, so uptake in these organs is extrane-
ous for patient image analysis. The main advantage of an
empty background was that the partial volume effect
could be dealt with straightforwardly. No partial volume
correction due to spill in of 124I background signal into
the signal of the vials was necessary. Additionally, correc-
tion for spill out from the vials was possible by drawing
relatively large fixed VOIs [16]. By using this method, vari-
able lesion volumes in the phantom were not a requisite.
Some practical issues of the calibration procedure could
be handled more straightforwardly by omitting back-
ground activity. For instance, no solution with a well-
known 124I background activity had to be produced,
making the phantom preparation less complex. Further-
more, legislation for the transportation of the reference
Fig. 4 Bland-Altman plots of measured activity Am,0 and calibrated activity Acal, versus reference activity Ar for all scanners, shown per vendor
(a vendor A and b vendor B). For presentation purposes, axes are on a log-log scale, and the relative errors are calculated as an absolute value:
Er =│(Ar − Am)/Ar│and Er =│(Ar − Acal)/Ar│. To assess improvement of calibration, the average of reference activities Ar and corresponding
average relative errors are calculated for each reference activity decade. The blue and green solid lines indicate the average relative errors in
measured and calibrated activities, respectively
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activities to all involved centers, as well as for the handling
of the activities at the centers, could be met with limited
effort due to the lower total activity.
The reference activities used to determine the calibra-
tion parameters are traceable to one standard activity.
The calibration procedure was designed to support a
multicenter study using the same supplier of 124I for the
study-related patient scans as for the calibration proced-
ure [3, 11]. Since production and activity assessment
protocols used by the supplier are standardized, activities
used in the calibration procedure and for patient scans
in the multicenter study are traceable to a higher stand-
ard. In this way, difficulties with activity assessment by
dose calibrators as described by Beattie et al. are over-
come [17]. However, if in the future multicenter studies
using isotopes are produced by more than one supplier,
reference activities should be related to a higher, prefera-
bly international, primary standard [18]. Potentially, or-
ganizations like EARL or EATRIS could play a pivotal
role in the development of these standards [12, 19].
The process of dilution and weighing used to pro-
duce the reference activities had the risk that an in-
exact reference activity concentration propagated to
the next lower concentration. However, this method
is most likely more accurate than that of direct meas-
urement with, e.g., a dose calibrator, due to the low
signal-to-noise ratio at low activities [17]. Therefore,
this process was preferred, while the risk of propaga-
tion of inaccurate concentrations was minimized with
an indicative, direct measurement of the produced ac-
tivity concentrations in each process step.
From the assessment of the precision, it appears
that after calibration, the relative error of the scan-
ners of both vendors exceeds the 50 % level at activ-
ity levels lower then 2–20 kBq (Fig. 4). It should
therefore be kept in mind that if in the clinical set-
ting the uptake is below these lower limits, reliable
quantification becomes inaccurate and should not be
used for dosimetric calculations. Additionally, this
method can be used to assess individual scanner pre-
cision in order to exclude underperforming scanners
from multicenter studies, provided that multiple mea-
surements per scanner are used.
Conclusions
A simplified multicenter calibration procedure for 124I
PET/CT scans in DTC is feasible and results in smaller
relative errors in 124I quantification. In the future, quan-
tification will be of growing importance especially in
multicenter clinical trials, and therefore, standardized
calibration procedures need to become applied widely.
Our procedure can be used in multicenter 124I PET
scans focusing on (recurrent) DTC.
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